Lung Cancer Clinical Trial
Perceptions on Expected Outcomes of Immunotherapy in Advanced Non-small Cell Lung Cancer Patients With Poor Performance Status
Summary
To better understand your feelings and expectations about immunotherapy
Full Description
Primary Objective:
1. To compare expectations of survival benefit from immunotherapy between advanced non-small cell lung cancer (NSCLC) patients with poor performance status (PS) and their oncologists. We hypothesize that, compared to their oncologists, patients will have expectations for greater likelihood of survival beyond 2 years.
Secondary Objectives:
To compare expectations of therapeutic benefit of immunotherapy between advanced NSCLC patients with poor PS and their oncologists. We hypothesize that, compared to their oncologists, patients will have expectations for greater likelihood of cure, quality of life improvement, and lower likelihood of adverse events.
To qualitatively describe the priorities and preferences for information of advanced NSCLC patients with poor PS when considering immunotherapy treatment.
To evaluate the associations between discrepant expectations with patients' sociodemographic and clinical characteristics.
To compare patient and oncologist expectations with actual treatment outcomes and survival
Eligibility Criteria
Inclusion Criteria:
Patients being considered for or within 2 months of starting immunotherapy for advanced NSCLC
Patient ≥18 years of age
ECOG ≥2
Cognitively able to understand consent and complete questionnaire as determined by the interviewer at the time of study enrollment
English speaking
Willing to participate in the study and sign informed consent
The study will include the oncologists that treat non-small cell lung cancer
Exclusion Criteria:
Treatment for curative intent
Presence of Delirium (as determined by score >13 on MDAS 46, appendix A)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Houston Texas, 77030, United States
How clear is this clinincal trial information?